NASDAQ$LFST
LifeStance Health Group Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
LifeStance reported a 21% increase in revenue, driven by increased visit volumes, and made progress in streamlining the business.
LifeStance Health Group, Inc. reported a 21% increase in fourth-quarter revenue to $229.4 million. The company's clinician base grew by 18% to 5,631, with 200 net clinician additions in the fourth quarter. The company is focused on streamlining and standardizing its business to pave the way for profitable and sustainable growth.
- Fourth quarter revenue increased 21% to $229.4 million.
- The clinician base increased 18% to 5,631 clinicians, including 200 net clinician adds in the fourth quarter.
- Net loss of $46.7 million in the fourth quarter, primarily driven by stock and unit-based compensation.
- Adjusted EBITDA of positive $10.2 million in the fourth quarter.
Headline financials
Revenue & EPS history
LifeStance · Revenue · Quarterly
$229M
Forward guidance
LifeStance expects full year 2023 revenue of $980 million to $1.02 billion, Center Margin of $270 to $290 million, and Adjusted EBITDA of $50 to $62 million.
Tailwinds
- Expecting full year 2023 revenue of $980 million to $1.02 billion
- Expecting Center Margin of $270 to $290 million
- Expecting Adjusted EBITDA of $50 to $62 million
- The Company expects total revenue of $242 to $252 million for the first quarter of 2023
- The Company expects Center Margin of $62 to $69 million for the first quarter of 2023
Headwinds
- Expecting Adjusted EBITDA of $7 to $12 million for the first quarter of 2023
- Focus remains on streamlining and standardizing our business over the next two years
- Adjusted EBITDA as a percentage of revenue decreased as a result of higher-than-expected G&A expenses in the fourth quarter
- Expecting Adjusted EBITDA of $50 to $62 million.
- Expecting full year 2023 revenue of $980 million to $1.02 billion
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2022
-4.5%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+1.2%
Avg return
30 days after
42%
8 / 19 earnings
Positive
+24.6%
Q4 2023
Best reaction
-49.7%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +19.8% | +7.7% | +0.5% | |
| Q4 2025 | +4.3% | +0.0% | -11.5% | |
| Q3 2025 | -3.6% | +29.1% | +30.1% | |
| Q1 2025 | -16.0% | -10.7% | -10.8% | |
| Q4 2024 | +3.1% | +6.8% | -10.8% | |
| Q3 2024 | +3.2% | +3.8% | +2.9% | |
| Q2 2024 | +1.6% | +6.0% | +26.1% | |
| Q1 2024 | -1.7% | +5.9% | -19.1% | |
| Q4 2023 | +24.6% | +21.8% | -3.4% | |
| Q3 2023 | -9.4% | -8.9% | +7.9% | |
| Q2 2023 | -5.0% | -7.4% | -17.1% | |
| Q1 2023 | -1.4% | +1.1% | +1.7% | |
| Q4 2022 | +22.2% | +23.8% | +65.6% | |
| Q3 2022 | -30.4% | -15.9% | -23.0% | |
| Q2 2022 | +6.2% | +10.8% | +29.3% | |
| Q1 2022 | -13.9% | +0.4% | +10.1% | |
| Q4 2021 | -12.7% | -5.9% | +4.2% | |
| Q3 2021 | -27.3% | -22.8% | -29.1% | |
| Q2 2021 | -49.7% | -40.6% | -30.2% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro